DEF: Windtree Seeks Shareholder OK for Capital, Reverse Split

Windtree Therapeutics seeks shareholder approval for significant capital raises, a reverse stock split, and increased authorized shares to support operations and maintain Nasdaq listing.

Summary

• A Special Meeting of Stockholders will be held virtually on August 28, 2025, at 10:00 a.m. Eastern Time, to vote on 10 proposals.
• Proposals 1-6 seek approval for the issuance of common stock upon conversion or exercise of various financing instruments, including Series D Convertible Preferred Stock, senior secured promissory notes, PIPE Warrants, Series E Convertible Preferred Stock, Series E Warrants, and an equity line of credit (ELOC).
• The Series D Private Placement generated approximately $3.0 million in gross proceeds, with an initial conversion price of $1.368 per share, potentially leading to approximately 8.6% dilution for existing stockholders.
• The Promissory Notes raised $4.3 million in gross proceeds (aggregate principal of $5 million) at an initial conversion price of $0.587 per share, potentially resulting in approximately 25.3% dilution, including 14% annual interest.
• PIPE Warrants have initial exercise prices of $0.587 or $1.10 per share, potentially leading to approximately 17.1% dilution upon full exercise.
• The Series E Private Placement is for approximately $60 million in gross proceeds initially, with a potential for an additional $140 million, at an initial conversion price of $0.30 per share. This could result in approximately 88.5% dilution initially, or up to 96.2% if the additional shares are sold.
• Series E Warrants have an exercise price of $0.75 per share, potentially leading to approximately 71.7% dilution, or 89.4% if additional Series E Preferred Stock is sold, assuming no conversion of Series E Preferred Stock.
• The ELOC with Seven Knots, LLC, allows for sales of up to $500 million in common stock at a purchase price of 96.5% of the closing price (or 90% if below $0.50), potentially resulting in approximately 94.7% dilution if fully utilized at an assumed price of $0.9726 per share.
• Proposal 7 seeks to increase the number of authorized shares of capital stock from 125,000,000 to 1,000,000,000.
• Proposal 8 aims to increase the shares reserved for issuance under the 2020 Equity Incentive Plan by 2,599,180 shares, bringing the total to 2,600,000 shares. CEO Jed Latkin is slated to receive 500,000 Restricted Stock Units (RSUs) if this proposal is approved.
• Proposal 9 requests approval for a reverse stock split at a ratio of no less than 1-for-2 and not greater than 1-for-25, to be determined by the Board's discretion, primarily to regain compliance with Nasdaq's minimum bid price requirement.
• The company received a Nasdaq deficiency letter on June 18, 2025, regarding its bid price falling below $1.00, and has a history of two prior reverse stock splits with a cumulative ratio exceeding 250-to-1.
• Proposal 10 seeks approval for adjournment of the Special Meeting if there are insufficient votes or a lack of quorum.
• The Board of Directors unanimously recommends stockholders vote FOR all 10 proposals.

Sentiment

Score: 3

Explanation: The company is addressing critical capital needs and Nasdaq compliance, which are positive for its continued operation. However, the sheer scale of potential dilution (up to 96.2% from Series E, 94.7% from ELOC), the very low conversion/exercise prices, high interest rates on debt, and a history of multiple reverse stock splits indicate severe financial distress and a highly unfavorable outlook for existing shareholders. The proposals are necessary for survival but come at a significant cost to current equity value.

Positives

• The proposed capital raises, totaling potentially over $700 million across various instruments, are crucial for satisfying ongoing business needs and implementing business plans.
• The increase in authorized shares provides the company with greater flexibility for future equity financings, investments, acquisitions, and employee incentive plans.
• The increase in shares for the 2020 Equity Incentive Plan aims to attract, motivate, and retain leading scientific and technical personnel, aligning employee interests with stockholder success.
• The reverse stock split is intended to help the company regain compliance with Nasdaq's minimum bid price requirement, preventing potential delisting.
• The Board of Directors unanimously recommends approval of all proposals, indicating internal alignment on these strategic actions.

Negatives

• Existing stockholders face severe dilution of ownership interests and voting rights due to the significant number of shares to be issued across all capital raising proposals (e.g., Series E alone could dilute up to 96.2%, ELOC up to 94.7%).
• The conversion and exercise prices for the new capital raises are very low ($0.30 for Series E, $0.587 for Promissory Notes/PIPE Warrants, $0.9726 average for ELOC), indicating a distressed valuation for new equity.
• The company has a history of persistent low stock price issues, having effected two reverse stock splits with a cumulative ratio of more than 250-to-1 in the prior two years, and is currently facing a Nasdaq bid price deficiency.
• There is no assurance that the reverse stock split will result in a sustained increase in the per share price or that the company will maintain Nasdaq listing.
• The Promissory Notes carry a high interest rate of 14% per annum, increasing to 24% upon an Event of Default, and holders can demand repayment from proceeds of other security issuances.
• The Series E investors, particularly the Lead Investor, could gain significant control, including the right to nominate two board members, potentially leading to the company being deemed a 'controlled company' under Nasdaq rules.
• The sale of newly issued shares into the public market could materially and adversely affect the market price of the common stock.

Risks

• Failure to obtain stockholder approval for the capital raising proposals could prevent the company from satisfying ongoing business needs, materially and adversely impacting future operating results, and resulting in a delay or abandonment of business plans.
• Failure to obtain stockholder approval for the reverse stock split could lead to the delisting of the company's common stock from The Nasdaq Capital Market.
• The reverse stock split may not result in a sustained increase in the per share price of the common stock, and the liquidity of the common stock could be adversely affected by the reduced number of shares outstanding.
• The issuance of additional authorized shares could have an anti-takeover effect by diluting the stock ownership of a person seeking to effect a change in control.
• The vesting of any portion of an award that is accelerated due to a change in control may be treated as non-deductible 'parachute payments' to the company and subject the recipient to a 20% federal excise tax.

Future Outlook

The company's ability to successfully implement its business plans and ultimately generate value for shareholders is dependent upon its ability to raise capital and satisfy ongoing business needs. Failure to obtain stockholder approval for the proposed capital raises could materially and adversely impact future operating results, and result in a delay in or modification or abandonment of business plans. The increased share reserve for the equity incentive plan is expected to be sufficient for approximately one year, based on anticipated growth and historical forfeiture rates.

Management Comments

• Our ability to successfully implement its business plans and ultimately generate value for its shareholders is dependent upon its ability to raise capital and satisfy our ongoing business needs.
• The Board believes it is in the best interest of our Company to increase the number of authorized shares of our common stock to give us greater flexibility in considering and planning for future potential business needs.
• The Board and Compensation Committee believe that we must continue to offer a competitive equity compensation program in order to attract, develop, motivate and retain leading scientific and technical personnel.
• The Board believes the Plan Amendment is necessary for us to continue to offer an equity incentive program that enables us to recruit, motivate and retain talented and highly qualified employees, directors and advisors who are critical to our future plans and our ability to successfully operate our business.
• The Company has monitored the closing bid price of our common stock and believes that the Reverse Stock Split is its best option for meeting the Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market.

Industry Context

The need for multiple, highly dilutive capital raises and a reverse stock split to maintain Nasdaq listing is indicative of a company, likely in the biotechnology or pharmaceutical sector (implied by 'Therapeutics'), facing significant financial challenges. Such companies often require substantial capital to fund research, development, and potential commercialization efforts, especially if they are pre-revenue or have limited commercial products. The terms of these financings, including low conversion prices and high interest rates on notes, suggest a challenging funding environment or a company in a precarious financial position relative to industry peers with more stable revenue streams or advanced product pipelines.

Comparison to Industry Standards

• The company's situation, requiring multiple highly dilutive capital raises and a reverse stock split to maintain Nasdaq listing, contrasts sharply with established pharmaceutical companies like Johnson & Johnson (JNJ) or Pfizer (PFE) which have robust revenue streams and do not typically resort to such measures for operational funding.
• Compared to early-stage biotech firms, the sheer scale of potential dilution (e.g., Series E alone up to 96.2%, ELOC up to 94.7%) is exceptionally high, suggesting a more severe capital need or less favorable terms than many peers might secure, even in the high-risk biotech space.
• The company's history of two reverse stock splits with a cumulative ratio of over 250-to-1 in the past two years, coupled with a current Nasdaq bid price deficiency, indicates a persistent inability to maintain a stable share price, which is worse than typical industry standards for publicly traded companies, even small-cap ones.
• The 14% annual interest rate (24% on default) for the Promissory Notes is significantly higher than typical corporate borrowing rates, reflecting a high-risk profile that is generally only seen in highly distressed or very early-stage ventures with limited collateral or revenue.

Management Changes

Corporate Governance

Related Party Transactions

• Strategic Advisor Agreements and an Asset Management Agreement are to be entered into with affiliates of Build and Build Corp (the Lead Investor in the Series E Private Placement).
• Compensation for services under Strategic Advisor Agreements includes Series E Preferred Stock and Series E Warrants.
• The Lead Investor has the right to nominate two members to the company's board of directors, contingent on holding at least 5.0% of common stock (or equivalents) purchased in the Series E Private Placement or the Strategic Advisor/Asset Management Agreements remaining in effect.

Stakeholder Impact

• **Shareholders**: Will experience significant dilution of ownership and voting rights due to the large number of shares to be issued across multiple capital raises at low prices. The market price of common stock could be materially and adversely affected by the sale of these new shares. Risk of delisting from Nasdaq remains despite the proposed reverse split.
• **Employees/Management**: The increase in the equity incentive plan aims to provide competitive compensation, aiding in attraction and retention of talent, and aligning their interests with long-term company success. The CEO is set to receive a substantial RSU grant.
• **New Investors (Series D, Notes, PIPE, Series E, ELOC)**: Have the opportunity to acquire significant equity at distressed valuations, potentially gaining substantial control and influence over the company. Promissory Note holders have senior repayment rights.
• **Creditors**: Promissory Note holders are senior secured obligations, providing them with a higher priority in repayment compared to equity holders.
• **Nasdaq**: The company is taking steps (reverse stock split) to comply with listing rules and avoid delisting, which is critical for maintaining public trading access.

Next Steps

• Hold the 2025 Special Meeting of Stockholders on August 28, 2025, to vote on the proposed amendments and issuances.
• If stockholder approval for Series D Convertible Shares is not obtained, the company is required to call subsequent meetings every 75 days until approval is secured or the Series D Preferred Stock is no longer outstanding.
• If stockholder approval for Series E Convertible Shares is not obtained at the first meeting, a second meeting must be called on or before November 13, 2025; failure to approve at the second meeting will result in automatic termination of the Series E Purchase Agreement.
• If Proposal 8 (amendment to the 2020 Equity Incentive Plan) is approved, the company intends to file a registration statement on Form S-8 covering the additional shares.
• The Board will determine the exact ratio (between 1-for-2 and 1-for-25) and timing of the reverse stock split if Proposal 9 is approved.
• The company will continue to monitor its common stock bid price to regain and maintain compliance with Nasdaq listing requirements.

Key Dates

Recommendation

The filing outlines a series of highly dilutive capital raises at significantly depressed valuations, coupled with a proposed reverse stock split to address a Nasdaq listing deficiency. The cumulative effect of these proposals, if approved and fully utilized, would result in extreme dilution for existing shareholders, potentially reducing their ownership to a negligible percentage. The company's history of multiple reverse stock splits and its current financial position, requiring such aggressive financing, indicate severe underlying distress. While these measures are necessary for the company's continued operation, they come at a substantial cost to current equity holders, making the stock a high-risk proposition with a strong likelihood of further value erosion for existing investors. The terms of the new capital infusions heavily favor new investors and the company's short-term survival over the interests of current shareholders.

Keywords

Windtree Therapeutics, WINT, SEC Filing, Proxy Statement, Capital Raise, Equity Financing, Reverse Stock Split, Nasdaq Listing, Stockholder Approval, Dilution, Preferred Stock, Promissory Notes, Warrants, Equity Line of Credit, Corporate Governance, Executive Compensation